<DOC>
	<DOCNO>NCT01637376</DOCNO>
	<brief_summary>The purpose study evaluate safety I-PDT Temoporfin patient Non-Resectable Non-Small-Cell Lung Cancer ( NR-NSCLC ) . Several clinical study suggest photodynamic therapy ( PDT ) may effective treatment patient NR-NSCLC . PDT therapy external light source , laser , use activate light-sensitive medicine produce byproduct destroy cancer cell . In study investigator use experimental light sensitive medicine , Temoporfin , perform interstitial PDT ( I-PDT ) . In I-PDT , laser fiber insert tumor activate light-sensitive medicine .</brief_summary>
	<brief_title>Photodynamic Therapy ( PDT ) With Temoporfin Non-Resectable Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Temoporfin</mesh_term>
	<criteria>Eighteen year age old , male female , race ethnicity . Histologically confirm nonsmallcell lung cancer ( NSCLC ) . Not candidate curative surgery . Not candidate curative concurrent chemoradiation therapy . Not candidate wish receive curative radiation therapy . Not candidate wish receive radiofrequency microwave thermal ablation . Have Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 . The tumor observable CT contrast . The tumor accessible unrestricted illumination interstitial photodynamic therapy ( IPDT ) . Deemed likely survive least 3 month . Patient able willing provide write informed consent participate study . If subject female childbearing potential , subject willing take pregnancy test practice strict birth control ( estrogencontaining oral contraceptive intrauterine device ) throughout study 3 month Temoporfin administration . Women hysterectomy exempt requirement . Subject willing remain control light exposure environment time period least 15 day . History laboratory test meet follow criterion Hematocrit &gt; = 33 % , hemoglobin &gt; = 11 g/dl Platelet count &gt; 70,000 per microliter White blood count &gt; 3,000 per microliter ANC &gt; 1500 per microliter Creatinine : 0.8 1.4 mg/dL Serum chloride : 101 111 mmol/L Serum potassium : 3.7 5.2 mEq/L Serum sodium : 136 144 mEq/L Liver function test : albumin , bilirubin ( direct/conjugated ) , ALT ( alanine transaminase ) , AST ( aspartate transaminade ) , GGT ( gamma glutamyl transferase ) , ALP ( alkaline phosphatase ) within normal limit BUN : 7 20 mg/dL The tumor invade major blood vessel . The tumor clearly show CT image . The tumor size large 5 cm measure contrast CT image accord RECIST v1.1 . The location extension tumor precludes effective IPDT . Patient porphyria disease exacerbate light . Patient hypersensitivity Temoporfin excipients . Patient known allergies/hypersensitivity porphyrin . Patient plan surgical procedure within next 30 day . Patient coexist ophthalmic disease likely require slitlamp examination within next 30 day . Patient exist therapy photosensitizing agent ( Temoporfin , porphyrin derivative porphyrin ) . Patient receive prior PDT propose treatment site within prior 3 month . Patient known sensitivity CT contrast agent ( Omnipaque ) , would preclude use CT contrast agent . History poor renal function demonstrate serum creatinine estimate glomerular filtration rate ( eGFR ) &lt; 40 mL/min/1.73m2 , would preclude use CT contrast agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Lung neoplasm</keyword>
	<keyword>Non Small cell lung carcinoma</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Large cell carcinoma</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>